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Abstract
Background: We retrospectively compared biochemical responses in type 1 Gaucher disease patients to treatment
with glycosphingolipid synthesis inhibitors miglustat and eliglustat and ERT.
Methods: Seventeen GD1 patients were included (n = 6 eliglustat, (two switched from ERT), n = 9 miglustat (seven
switchers), n = 4 ERT (median dose 60U/kg/m). Plasma protein markers reflecting disease burden (chitotriosidase,
CCL18) and lipids reflecting substrate accumulation (glucosylsphingosine, glucosylceramide) were determined.
Also, liver and spleen volumes, hemoglobin, platelets, and fat fraction were measured.
Results: In patients naïve to treatment, chitotriosidase, CCL18 and glucosylsphingosine decreased comparably
upon eliglustat and ERT treatment, while the response to miglustat was less. After 2 years, median decrease of
chitotriosidase was 89 % (range 77–98), 88 % (78–92) and 37 % (29–46) for eliglustat, ERT and miglustat naïve
patients respectively; decrease of CCL18 was 73 % (63–78), 54 % (43–86), and 10 % (3–18); decrease of
glucosylsphingosine was 86 % (78–93), 78 % (65–91), 48 % (46–50). Plasma glucosylceramide in eliglustat treated
patients (n = 4) reached values below the normal range (n = 20 healthy controls). Biochemical markers decreased or
stabilized in switchers from ERT to eliglustat (n = 2), but less in miglustat switchers (n = 7). Clinical parameters
responded comparably upon eliglustat and ERT treatment.
Conclusions: Our explorative study provides evidence that biochemical markers respond comparably in patients
receiving eliglustat treatment and ERT, while the corresponding response to miglustat treatment is less.
Keywords: Gaucher disease, Eliglustat, Miglustat, Chitotriosidase, Glucosylsphingosine, Glucosylceramide, Enzyme
replacement therapy
Background
Gaucher disease type I (GD1, OMIM230800) results
from a deficiency of glucocerebrosidase (GBA1), a lyso-
somal enzyme responsible for the degradation of gluco-
cerebroside (GlcCer) and glucosylsphingosine (GlcSph)
[1, 2]. Subsequently, GlcCer and GlcSph accumulate,
leading to the characteristic lipid laden macrophages,
also known as Gaucher cells. These are thought to play
a vital role in GD1’s pathophysiology, causing symptoms
of hepatosplenomegaly, cytopenia and debilitating bone
complications. Enzyme replacement therapy (ERT), cur-
rently the standard treatment of GD1, targets correction
of these macrophages by intravenous administration of
modified glucocerebrosidase. Three recombinant gluco-
cerebrosidase products are approved for the treatment
of GD1: imiglucerase (Genzyme a Sanofi Company),
velaglucerase alpha (Shire Human Genetic Therapies)
and taliglucerase alpha (Protalix Biotherapeutics). All
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demonstrate remarkable improvement of cytopenias and
hepatosplenomegaly [3–8]. Nonetheless there are im-
portant limitations of ERT. Besides inconvenient infu-
sions and exorbitant costs, there is increasing evidence
that ERT cannot completely prevent bone complications
[9]. In particular patients with bone disease at start of
therapy can experience despite treatment additional bone
complications, although the frequency of such events
seems reduced [10]. It has been suggested that a systemic
therapy targeting not only macrophages might be more
beneficial, as aspects of GD’s symptomatology (malignan-
cies, pulmonary hypertension, Parkinson’s disease and
osteoporosis) are insufficiently explained by macrophage
involvement solely [11].
Substrate reduction therapy (SRT), aiming to reduce
accumulating glycosphingolipids by inhibiting their
synthesis, might circumvent these disadvantages of ERT.
Inhibitors of GlcCer synthesis to be used in SRT of GD1
are small compounds that can be taken orally and have
the potential to rapidly diffuse into various tissues, in-
cluding bones and the central nervous system. For GD1
presently inhibitors of the enzyme glucosylceramide
synthase (GCS) have been developed. The first devel-
oped GCS inhibitor was miglustat (Actelion Pharmaceu-
ticals Ltd.), which over a decade ago was approved for
mild to moderately affected GD1 patients unsuitable to
receive ERT. Significant improvements in hepatospleno-
megaly and biochemical markers have been observed
with miglustat treatment [12–14]. Although direct com-
parison with ERT has never been properly studied, the
effects on key clinical parameters are less robust. Side
effects such as gastrointestinal complaints (up to 80 %)
and tremors in many cases have led to discontinuation
of treatment. These side effects limit the use of miglustat
for patients with GD [12, 13]. Although miglustat is able
to cross the blood brain barrier in mouse models, effects
on neurological outcomes in type III GD are controver-
sial [15, 16]. Eliglustat tartrate (abbreviated to eliglustat,
Genzyme a Sanofi Company) is a new GCS inhibitor
with a stronger inhibitory potency than miglustat (IC50
value of 0.024 μM vs. 5–50 μM). Eliglustat does not
cross the blood brain barrier. In contrast to miglustat,
eliglustat does not potently inhibit intestinal glycosi-
dases, thus largely preventing the gastro-intestinal symp-
toms observed with miglustat [17]. Eliglustat has shown
high promise as an oral treatment for GD1 given the
observed clinically relevant effects on hematological and
visceral symptoms [18–22].
In GD1, well established plasma markers reflecting
disease burden have been described. Chitotriosidase
(CHIT1 gene) and pulmonary and activation regulated
chemokine (CCL18/PARC), both produced and secreted
by macrophages, reflect to some extent the total burden
of Gaucher cells [23, 24]. Chitotriosidase and CCL18
correlate with several clinical parameters [25, 26] and
failures in correction of high levels of chitotriosidase are
associated with the incidence of long term complications
[26]. The use of plasma chitotriosidase in monitoring of
GD1 patients has limitations, because chitotriosidase
activity is subject to genetic heterogeneity. Roughly 6 %
of the population has no chitotriosidase activity due to a
24-bp duplication in the CHIT1 gene [27, 28]. More
importantly a common G102S CHIT1 polymorphism
renders misleading data of chitotriosidase protein levels
when using the commercial substrate 4-methylumbelliferyl-
chitotrioside as a substrate [29]. This can be prevented using
the novel 4-methylumbelliferyl-deoxychitobiosidase substrate
[29, 30]. Even with the optimized 4-methylumbelliferyl-
deoxychitobioside substrate the use of internal standards of
recombinant chitotriosidase is warranted. Data produced by
laboratories not using such internal controls should be
interpreted with caution. In chitotriosidase-deficient GD
patients CCL18 is frequently used to monitor GD1 disease.
Little is known about intra-individual variations due to poly-
morphisms in the CCL18 gene. A more recent improvement
is the use of plasma GlcSph as a marker of Gaucher cell
burden. The sphingoid base is on average 200 fold elevated
in GD1 patients [31]. The main source of the elevated
GlcSph in GD1are lipid-laden macrophages, but all GBA
deficient cells in GD patients may produce GlcSph lo-
cally [31]. In contrast to CCL18 and chitotriosidase,
GlcSph is directly related to the primary molecular
defect in GD1 patients. There is some evidence that
GlcSph in GD1 is largely formed from intralysosomal
GlcCer by deacylation [31–33]. Recent studies with
conditional GD1 mouse models provide some evi-
dence for the hypothesis that abnormalities in
GlcSph contribute to GD1 symptomatology [11, 31,
32, 34, 35].
Until now a direct comparison of effects on biochem-
ical markers reflecting disease burden between the
aforementioned SRT and ERT treatment modalities has
not been available. In this study, the effects on plasma
markers of disease burden (chitotriosidase, CCL18, and
GlcSph), plasma GlcCer associated to lipoproteins and
clinical response (visceral, hematological and skeletal)
are compared among eliglustat, miglustat and ERT
treated patients.
Methods
Patients
All Dutch Gaucher patients treated with eliglustat and
miglustat were eligible and included in this case series
study. To compare clinical effects between treatment
modalities, eliglustat treated patients (naïve to ERT ther-
apy) were matched to ERT treated patients based on
disease severity (absence of splenectomy and bone com-
plications) and gender. Miglustat patients (naïve to ERT
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therapy) could not be matched due to small sample size.
All ERT treated patients were receiving similar doses of
ERT and had available fat fraction scores. Treatment fail-
ure was defined as published earlier [26]. A diagnosis of
Gaucher disease was confirmed by GBA genotyping and
demonstration of deficient glucocerebrosidase activity in
leucocytes. Clinical assessments consisted of hemoglobin
levels, platelets count and abdominal Magnetic Reson-
ance Imaging (MRI) to assess liver and spleen volumes.
Bone marrow infiltration was assessed using Dixon
Quantitative Chemical Shifting Imaging (QCSI) of the
lumbar spine [36].
In the Dutch cohort in total six patients received eli-
glustat as part of a trial program from Genzyme, a
Sanofi company. All patients were treated with eliglustat,
albeit in different dosing regimens and frequency (once
or twice daily, see Table 1). Per protocol doses were
adjusted based on plasma trough level of eliglustat. Five
patients used 200 mg once or 100 mg twice a day, and
one used 50 mg twice a day (patient 2).
A study protocol to obtain extra blood samples for
patients treated with eliglustat was approved by the
institutional review board of the Academic Medical
Centre (AMC), Amsterdam, the Netherlands. Written
informed consent was obtained from all participants.
Data and samples of ERT and miglustat treated patients
were gathered from the AMC biobank, for which all pa-
tients signed an informed consent. All investigations
were conducted according to the declaration of Helsinki.
Biochemical plasma markers
Biochemical markers were measured in non-fasted plasma
samples, stored at -20 °C. Chitotriosidase activity was
measured using the 4MU-deoxychitobiosidase substrate,
as described [28, 30], using a recombinant chitotriosidase
as internal standard. All chitotriosidase values of patients
heterozygous for the 24-bp duplication in the CHIT1 gene
were multiplied by 2 [27, 28]. Plasma CCL18 was deter-
mined by ELISA as described previously [23].
Glycosphingolipids were extracted as previously de-
scribed using the Bligh and Dyer method. Briefly, 500 μL
CHCl3/MeOH was added to 25 μL of plasma, in a 2:3
ratio (v:v), and samples were centrifuged for 3 min at 16
000 g to remove protein precipitate. Subsequently,
100 μL CHCl3 and 255 μL 100 mM formate buffer
pH 3.15 was added for phase separation. After vortexing
and centrifugation for 3 min at 16 000 g, the upper or-
ganic phase was collected, and lower phase re-extracted
with 300 μL MeOH and 270 μL formate buffer. Pooled
upper phases were desiccated in a heat block set at (37 °C)
using mild N2 flow. Dried samples were redissolved in
100 μL MeOH and glucosylsphingosine was analysed by
LC-ESI-MS/MS using 13C5-GlcSph as internal control
[37] Ceramide and glucosylceramide were determined in
the lower phase by HPLC as described in reference [38]
using C17 sphinganine as an Internal Standard (Avanti
Polar Lipids, Alabama, USA).
Statistical analyses
For statistical calculations and data collection, SPSS ver-
sion 20 was used (SPSS Inc. Chicago, IL). Graphs were
made in GraphPad Prism version 6. For descriptive data,
medians and ranges were used. Statistical tests to
compare effects between groups were not performed
due to small sample size.
Results
Patients
Of the included patients six were treated with eliglustat:
four were naïve to treatment (‘naïve patients’) and two
had been treated with ERT for 18 or more years (‘switch
patients’). One switch patient (Table 1, no. 12), severely
affected at initiation of ERT (multiple disabling bone
complications, splenectomy), interrupted eliglustat treat-
ment after 17 weeks because of an AE possibly related
to eliglustat use (data reported to Genzyme a Sanofi
Company). Nine miglustat treated patients were in-
cluded of whom two were naïve to treatment. Seven pa-
tients switched from ERT to miglustat: three because of
a worldwide imiglucerase shortage (no. 15, 16, 17), three
because they preferred an oral treatment and were clin-
ically stable on ERT (no. 13, 14, 18), and one because of
treatment failure on imiglucerase due to development of
neutralizing antibodies (no. 19, depicted in graphs with a
blue star), earlier described in an abstract and case re-
port [39, 40]. Two patients interrupted treatment be-
cause of tremors and three because of treatment failure
(described more in detail below). The four patients
treated with eliglustat and naïve to ERT were matched
to four ERT treated patients (see method section and
Table 1), receiving a median dose of 60 U/kg/month
(range 45–60) albeit with different enzyme preparations
(velaglucerase or imiglucerase).
Chitotriosidase, CCL18 and GlcSph in patients naïve to
treatment
Figure 1 graphs A–F and Table 2 demonstrate that while
plasma chitotriosidase, CCL18 and GlcSph levels de-
creased comparably in patients treated with eliglustat and
ERT, in miglustat treated patients these decreases were
less prominent (of note, one patient had bone complica-
tions and a splenectomy suggesting more severe disease).
After two years of therapy none of the investigated
markers normalized completely, irrespective of treatment
modality. The reduction during the first three months of
therapy of these markers was comparable between ERT
and eliglustat treated patients.
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Table 1 Baseline characteristics of included GD1 patients
Patient Gender Age start therapy [yr] GBA Mean dose
ERT [U/kg/m]
SRT [mg/day]
CYP2D6
Genotype
ERT before
switch [yr]
Stop SRT/SRT
duration [yr]
Anemia
[g/dL]
T0/TSwitch
Platelets
[a109/L]
T0/TSwitch
Sx Spleen [mL]
T0/TSwitch
Liver [mL]
T0/TSwitch
Bone
complications
FF [%]
T0/TSwitch
Naive patients Eliglustat 1 M 59 N370S/L444P 200 IM na - 12.6 76 - 888 2037 - 37
2 M 42 N370S/L444P 100 IM na - - 96 - 1700 2679 - 38
3 M 43 N370S/L444P 200 EM na - - 117 - 797 2728 - 29
4 F 37 N370S/L444P 200 EM na - - 154 - 642 2031 - 7
ERT 5 M 47 N370S/L444P 45 - na na - 118 - 855 2269 - 18
6 M 45 N370S/P319L 60 - na na - 69 - 2115 3347 - 33
7 M 42 N370S/c.1265_1319del 60 - na na 13.5 78 - 508 1776 - 24
8 F 46 RecNci/D140H 60 - na na - 38 - 932 1733 - 44
Miglu. 9 F 44 N370S/L444P 500 - na - - 95 - 1412 2818 - 23
10 F 43 N370S/R131C 300 - na - 11 268 + na 2590 + 16
Switch patients Eliglu. 11 M 37 N370S/L444P 15/200 EM 18 - -/- 110/174 - 574/310 1830/1719 - 29/51
12 M 36 N370S/G202R 34/200 EM 20 AE/0.33 12.6/12.7 281/281 + na 2257/1327 + naa
Miglustat 13 M 43 N370S/L444P 15/300 - 12 - -/- 45/162 - 885412 2014/1615 - 40/56
14 M 47 N370S/L444P 34/300 - 13 - 11.3/- 53/100 - 3118/1855 3334/2193 - 24/52
15 F 32 N370S/D409H 15/300 - 9 TF/0.73 11.1/- 41/155 - 766/232 2485/1832 - 7/45
16 F 65 N370S/L444P 30/300 - 8 AE/0.23 11.9/- 76/192 - 1561/323 2730/1851 - 16/34
17 F 12 N370S/L444P 30/300 - 11 AE/0.41 11.9/- 90/143 - 933/409 1682/1725 - 18/38
18 F 30 N370S/EX9delG 30/300 - 7 TF/0.68 -/11.9 129/161 + na 3293/1604 - 23/33
19 F 23 N118S/N118S 30/200 - 2 TF/2.2 10.8/7.3 46/52 - 952/1557 2005/1878 - 4/4
Of the patients switching from ERT to SRT baseline data are given before start of ERT (T0) and before start of SRT (Tswitch). Dosing represents the mean dose of ERT/SRT during first two years of treatment. Anemia is
defined as M < 13.7, F < 12.1 g/dL. a due to severe bone complications fat fraction cannot reliably be measured. Abbreviations: M males, F females, IM intermediate metabolizer, EM extensive metabolizer, na not
applicable, +: present, -: absent, ERT enzyme replacement therapy, SRT substrate reduction therapy, Sx splenectomy, AE adverse events, TF treatment failure, FF fat fraction
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Chitotriosidase, CCL18 and GlcSph in patients switching
from ERT to SRT
Only two patients switching from ERT to eliglustat were
available. Patient 11, a mildly affected patient switching
from ERT to eliglustat, demonstrated a further decrease
of chitotriosidase and GlcSph while CCL18, already nor-
malized on ERT, remained constant. Despite the fact that
patient 12 was only treated with eliglustat for a short
Fig. 1 Plasma chitotriosidase, CCL18, glucosylsphingosine (GlcSph) and glucosylceramide (GlcCer) in patients naïve to treatment. Graphs a, b, d, e,
g, h, j, k: represent absolute marker levels. Graphs c, f, i, l: represent median of individual relative levels compared to each individual T0 sample
(100 %) per treatment modality. Dotted lines represent reference values (chitotriosidase: 7–187 nmol/mL.hr, CCL18: 10–72 ng/mL, GlcSph 0.8–2.7
pmol/mL, GlcCer 3.7–8.2 nmol/mL)
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period of time (17 weeks), he demonstrated a decline in
chitotriosidase, which was still very high after 20 years
of ERT (8572 nmol/mL.hr). Of note, this patient also
showed a transient reduction in plasma GlcSph. In pa-
tients switching from ERT to miglustat, plasma chito-
triosidase (5/7), CCL18 (5/7) and GlcSph (6/7) increased
in most patients in comparison to their levels before
switch (Fig 2a–d). At the last available sample before
discontinuation (combined with the sample after two
years of treatment in those not interrupting treatment,
sample range 0.23 to 2 years), chitotriosidase increased
with a median of 78 % (range -14 to +134), CCL18 28 %
(range -13 to +83 %) and GlcSph 63 % (range -34.7 to
+143 %).
Plasma GlcCer and Ceramide in patients naïve and
patients switching from ERT to SRT
To compare the inhibitory response of eliglustat and
miglustat on GlcCer synthesis at cellular level, tissue bi-
opsies would have been essential. Because these were
not available we investigated plasma GlcCer levels,
mostly reflecting hepatic GlcCer synthesis bound to
lipoproteins, and spill-over of accumulated GlcCer.
Plasma GlcCer levels decreased rapidly below lower limit
of normal (of n = 20 healthy control subjects), both in
naïve and switchers treated with eliglustat (Figs. 1j and
2d). Decreases were observed already after two weeks of
treatment (data not shown). Such rapid decline of
plasma GlcCer and GlcSph was not observed in any of
the miglustat treated patients. Of note, we observed an
unexpected transient increase of GlcCer and GlcSph in
5/6 patients in samples taken 4 h after their first dose of
eliglustat (data not shown). Whether this unexplained
effect is specific to eliglustat could not be investigated as
short term samples were not available from ERT and
miglustat treated patients. In contrast, in most miglustat
treated patients, especially those who switched from
ERT (5/7), plasma GlcCer increased to supra-normal
levels. Upon ERT treatment plasma GlcCer levels de-
creased in all, but normalized in 3/4 patients treated
with ERT only, and normalized in 2/7 switch patients
just before they switched to miglustat.
Plasma ceramide levels did not increase upon different
treatment modalities in naïve or switch patients: T0 eli-
glustat 6.6–12.8 nmol/mL, ERT 8.0–15.0 nmol/mL,
miglustat 6.6–10.6 nmol/mL (normal reference range:
5.1–18.8 nmol/mL) versus after two years of treatment
T2yr eliglustat 7.6–12.8 nmol/mL, ERT 8.0–10.0 nmol/
mL, miglustat 4.8–10.1 nmol/mL.
Clinical response
Eliglustat
Eliglustat treated patients naïve to treatment were mildly
affected by GD1 at initiation of therapy. Figure 3 dem-
onstrates the good clinical response to the drug treat-
ment: liver and spleen volumes decreased, platelet
counts increased and no bone complications occurred.
Hemoglobin levels improved in those with anemia at
baseline. Bone marrow fat fraction levels increased in all
patients upon eliglustat treatment: three normalized
their fat fractions by one year and the fourth increased
above a threshold (0.23) associated with an increased
risk of fractures [36]. These improvements are indicative
of clearance of Gaucher cells from the bone marrow
compartment (Figs. 3i and 4).
Of the two switch patients, one (no. 12) was a severely
affected patient with splenectomy and multiple bone
complications prior to initiation of ERT. Twenty-two
years of ERT had resulted in a normal liver volume, but
residual bone disease with high plasma chitotriosidase
levels. He interrupted treatment with eliglustat after
17 weeks due to an AE. All clinical GD parameters
remained stable, but the period of observation was too
short to draw any conclusions. Patient 11, mildly af-
fected at start of ERT, had stable spleen and liver vol-
umes, platelets counts and hemoglobin levels, which
were all normal when eliglustat was initiated and
remained stable.
Miglustat
Miglustat patients had variable disease severity at initi-
ation of ERT. Of the two patients treated with miglustat
and naïve to ERT, one splenectomized patient with bone
complications (no. 10), showed a gradual decline of liver
volume, comparable to ERT and eliglustat patients
(Fig. 3a). After 15 years of treatment this patient kept
borderline anemia (Hb levels T0 10.9 to T15 10.9 g/dL)
without other causes for her anemia than GD1. The
non-splenectomized patient had a decline in organome-
galy, which was similar to effects seen with ERT and eli-
glustat during the follow-up of two years. Evaluation
after 15 years of treatment showed stabilization with
Table 2 Median percent decrease (range) of biochemical
markers in treatment naïve patients
Eliglustat ERT Miglustat
n = 4 n = 4 n = 2
Year Median (range) Median (range) Median (range)
Chitotriosidase 1 68.3 (40–80.9) 79.6 (61.9–91.1) 41.8 (41.4–42.2)
2 88.8 (77–97.7) 88.1 (77.9–91.9) 37.3 (28.9–45.6)
CCL18 1 45.4 (35.3–52.9) 43.1 (21.5–65) -9.6 (-22.1–2.9)
2 72.9 (62.7–78.3) 53.7 (43.4–85.7) 10.3 (2.8–17.7)
GlcSph 1 75.9 (62.4–78.3) 71.9 (20.6–81.3) 25.8 (23.8–27.7)
2 86.2 (78.4–92.9) 78.4 (64.7–90.6) 47.8 (45.4–50.2)
GlcCer 1 79.8 (76.4–89.4) 35.1 (-6.9–56.8) 37.6 (37.5–37.6)
2 84.1 (74.3–90.6) 36.4 (19–67.1) 39.5 (25.3–53.6)
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moderate thrombocytopenia (100 × 109/L) and spleno-
megaly (406 mL, 3 times multiple of normal). Fat frac-
tions increased in both patients (Fig. 3i).
Of the seven patients switching to miglustat two
remained clinically stable (no. 13 and 14). Two patients
discontinued treatment shortly after initiation of
Fig. 2 Plasma chitotriosidase, CCL18, glucosylsphingosine (GlcSph) and glucosylceramide (GlcCer) in patients previously treated with ERT. a–d:
individual levels. Dotted lines represent reference values (see legend Fig 1). Time between start ERT and SRT is variable between patients (range
7–13 year). * blue star indicates patient no 19
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Fig. 3 (See legend on next page.)
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miglustat due to AEs and three patients discontinued
due to treatment failure (see Table 1). The first had an
increase of spleen volume and a decrease of fat fraction,
while the second had an increase of liver volume and
decrease of fat fraction The third case (patient 19) was
switched to miglustat due to disease progression as the
consequence of neutralizing antibodies to imiglucerase.
She further deteriorated on miglustat treatment with an
increase of liver volume, development of severe
thrombocytopenia and a bone complication with very
low fat fraction (see blue star * in Figs. 2, 3). In all
patients who had a treatment failure, the biochemical
markers chitotriosidase and CCL18 worsened upon start
of miglustat treatment.
Discussion
Our investigation with a limited number of naïve GD1
patients suggests that the response to eliglustat treat-
ment with respect to established biomarkers of disease
burden (chitotriosidase and CCL18) is on a par with that
of moderate doses of ERT. In contrast, the same bio-
markers respond less favorably to miglustat treatment.
(See figure on previous page.)
Fig. 3 Clinical response of different treatment modalities in naïve patients (graphs ACEGI) and switching from ERT to SRT (graphs BDFHJ). Follow
up of patients 15 and 16 is incomplete due to early treatment discontinuation. a, b Liver volume. c, d Spleen volume. e, f Platelet count,
splenectomized patients are depicted in dotted lines. g, h Hemoglobin levels, splenectomized patients are depicted in dotted lines. i, j Average
bone marrow fat fraction of corpora L3, L4, L5 (data are missing of patient 12. Due to multiple bone complications fat fraction assessments are
not reliable, patient 16 and 17 because of early treatment discontinuation). Below the indicated threshold value of 0.23 (black dotted-line), the risk
for bone complications is increased. * blue star indicates patient 19
Fig. 4 Changes in bone marrow fat fraction during 2.5 years of eliglustat treatment. Depicted are patient no. 3 and 4 who had the most severe
decrease of fat fraction before initiation of therapy and showed most prominent increases of fat fraction upon eliglustat treatment. Fat fraction
values of patient 4 before initiation of therapy ranged between 7–20 %, probably related to hormonal variation [53]. Fat fraction scores of L3, L4,
and L5 are averaged. Patients with a fat fraction <0.23 have an increased risk of developing bone complications [36]
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These findings are in agreement with literature reports.
Mistry et al demonstrated that after 9 months of eliglu-
stat treatment in naïve GD1 patients chitotriosidase de-
creased with a mean of 44 % [21]. Lukina demonstrated
a median decrease of CCL18 of 50 % [19], while in naïve
GD1 patients treated with miglustat mean decreases of
chitotriosidase after one year were less pronounced, ran-
ging from 6 to 17 % [12, 41–44], median 5–13 % (me-
dian values were not given, but could be calculated from
references [12, 42]).
Next, our investigation showed that seventy percent of
patients switching from ERT to miglustat demonstrated
an increase of plasma chitotriosidase levels. The preva-
lence of such deterioration is higher than reported in lit-
erature, where increases are described in 4–43 % of
cases [13, 44–46]. The small number of patients investi-
gated might explain this disparity. There may also be
bias in studies due to high drop-out rates by AE’s and
treatment failure. In addition, the outcome of the switch
from ERT to miglustat may be influenced by specific
reasons, for instance the severely affected patient no 19
in our investigation had to switch due to antibody devel-
opment towards imiglucerase. Since increases of plasma
chitotriosidase are not always directly accompanied by
prominent clinical deterioration [45], the value of chito-
triosidase measurements to monitor GD1 patients
deserves discussion. Recently van Dussen et al demon-
strated that patients with sustained chitotriosidase in-
creases ≥ 30 % are at risk of having clinical deterioration
with a relative risk of 6.3 (CI 95 % 2.2–17.8): chitotriosi-
dase increases are accompanied by clinical deterioration
in 50 % of patients, whereas when chitotriosidase is
stable, 8 % develop clinical deterioration [26]. Sustained
increases of chitotriosidase after switch from ERT to
miglustat reflect an increase of Gaucher cell burden and
risk for clinical deterioration or new complications,
which should therefore be avoided. In addition, van
Dussen showed that high residual chitotriosidase activity
after two years of treatment correlates to long term
complications. Although limited patients switching from
ERT to eliglustat were available in this study, it is
reassuring that even after ±3 months of therapy in a
severely affected GD1 patient with high residual chito-
triosidase activity after 20 years of ERT, eliglustat was
able to decrease chitotriosidase and CCL18 levels. Even
more promising is the noted transient reduction in
plasma GlcSph in this patient. This anecdotal finding
suggests that eliglustat might be capable in some GD1
patients to reach Gaucher cells that are not responsive
to ERT. Our investigation documents for the first time
that elevated plasma GlcSph is comparably decreased by
eliglustat and ERT in naïve GD1 patients. The two inves-
tigated patients who switch from ERT to eliglustat treat-
ment showed a further reduction of plasma GlcSph
levels. On the other hand, miglustat treatment of naïve
GD1 patients led to only minor reductions and switch-
ing patients from ERT to miglustat tended to be associ-
ated with stable or increasing plasma GlcSph. The
clinical implications of the elevated plasma GlcSph are
yet unclear, like those of elevated plasma GlcCer. From
the single study that addressed associations with clinical
symptoms, it can be concluded that it could be seen as a
general marker for disease burden in GD1 [31], but does
not correlate to specific symptoms. In contrast to chito-
triosidase, which is not pathogenic but a mere reflection
of alternatively activated macrophages, it has been hy-
pothesized that GlcSph as a toxic compound is directly
implicated in GD1 pathology. Studies of Orvinsky and
Nilson revealed that GlcSph levels were normal in a
brain of a GD I patient, but elevated in GD III and high-
est in brains of GD II patients with the most severe cere-
bral involvement [47, 48]. In vitro studies suggest
neurotoxicity of GlcSph [49]. In addition, GlcSph has
been shown to cause hemolysis and to inhibit protein
kinase C, a pivotal kinase in signal transduction and cell
behavior [31]. Extrapolation of such in vitro findings
with high concentrations of GlcSph to pathophysio-
logical action in GD patients warrants care. Further cir-
cumstantial evidence of a toxic effect of GlcSph in GD1
has been offered by Mistry et al demonstrating that high
levels of GlcSph impair osteoblastogenesis in cultured
osteoblasts of a conditional mouse GD1 model demon-
strating very low bone mineral density [11]. More re-
cently, Pavlova et al suggested that GlcSph is oncogenic,
based on the association of high GlcSph levels in a
conditional mouse model with a high incidence of B-cell
lymphoma [34, 35]. If further research substantiates that
GlcSph contributes to the pathogenesis of GD1, ERT
treated patients with remaining high levels of GlcSph
might potentially benefit from eliglustat treatment.
Of note, our study confirms that eliglustat is a very
potent inhibitor of GCS in humans. Whereas with
miglustat plasma GlcCer normalized or increased, eliglu-
stat dramatically decreased circulating GlcCer bound to
lipoprotein in all eliglustat patients, even to levels 50 %
below normal as determined for 20 healthy subjects.
However, it is essential to analyze a much larger number
of presumed normal subjects to establish the lowest
limit of the normal population range.
Due to limited sample size our study is insufficient to
draw definite conclusions whether ERT and eliglustat are
on a par in clinical efficacy. Nonetheless, our data for
the matched patients indicate that eliglustat is not infer-
ior to moderate dose of ERT: an equal decline of liver
and spleen volumes, and equal rise of platelets and fat
fraction was observed. Extended comparative data on
both treatment modalities are now essential to deter-
mine the optimal clinical strategy for naïve GD1
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patients. Such data are not actively pursued. The pres-
ently conducted RCTs by Genzyme do not directly com-
pare ERT to eliglustat treatment of naïve GD1 patients.
Instead, eliglustat treatment is compared to placebo [21].
Safety of switching from ERT to eliglustat treatment is
separately investigated [22]. The RCT comparing placebo
to eliglustat, including mild to moderately affected pa-
tients (severe patients with bone disease and splenecto-
mies were excluded), demonstrates clinically relevant
responses on cytopenia and hepatosplenomegaly [21].
Results of the ENCORE trial [22] demonstrate that 85 %
(84/99) of the eliglustat treated GD1 patients (pretreated
with ERT) and 94 % (44/47) of imiglucerase treated pa-
tients maintained therapeutic goals. Eliglustat treatment
was statistically non-inferior to imiglucerase treatment
as the lower bound of the 95 % confidence interval dif-
ference was within pre-specified non-inferiority thresh-
olds (-17.6 %).
Potential advantages of present and future SRT modal-
ities are thought to be better prevention of bone compli-
cations due to drug delivery in the bone compartments.
In our naïve GD patients, bone marrow infiltration (fat
fraction) improved upon eliglustat therapy, and none de-
veloped bone complications during the study period.
With the available limited clinical data is not possible to
draw conclusions on superiority of eliglustat treatment
over ERT regarding bone complications. It will be also
of interest to learn how eliglustat treatment impacts the
occurrence of long-term complications and associated
conditions in GD1 such as cancer, pulmonary hyperten-
sion, metabolic alterations including insulin resistance as
well as Parkinson’s disease [50–52].
Conclusions
Our exploratory investigation with a small number of
GD1 patients has indicated that response in biomarkers
of disease burden is on a par in naïve patients receiving
eliglustat treatment and those receiving moderate doses
of ERT, the same biomarkers responded less to miglustat
treatment in (very limited sample size). Clinical response
in the compared ERT and eliglustat treated naive GD pa-
tients seemed also comparable. Our present biochemis-
try and clinical findings should be extended by studies
with larger cohorts.
Competing interests
MJF, MV, MM, PW, HSO and JMA declare that they have no competing
interests.
BES: received travel support and reimbursement of expenses from Genzyme,
a Sanofi company.
CEH: has acted occasionally as consultant for Genzyme, Shire HGT, Actelion
or Protalix and received reimbursement of travel costs and fees for invited
lectures. All financial arrangements are made with AMC Research BV. AMC
receives financial support to submit patient data to the registries from
Genzyme and Shire, and has received unrestricted grants for research and
courses in the field of lysosomal storage disorders.
Authors’ contributions
BES: design study, data acquisition and interpretation, drafting manuscript.
MJF: data acquisition and interpretation, drafting manuscript. MV: data
acquisition and interpretation, manuscript revision. MM, PW, HO: contributed
to the development of MS/MS method, manuscript revision. CH: design
study, interpretation data, manuscript revision. JA: design study,
interpretation data, manuscript revision. All authors read and approved the
final manuscript
Acknowledgements
We would like to thank all participating patients and Maaike Wiersma for her
assistance in the collection of samples.
Author details
1Department of Endocrinology and Metabolism, Academic Medical Centre,
Amsterdam, The Netherlands. 2Department of Medical Biochemistry,
Academic Medical Centre, Amsterdam, The Netherlands. 3Department of
Biochemistry, Leiden Institute of Chemistry, Leiden University, Leiden, The
Netherlands. 4Department of Bio-Organic Synthesis, Leiden Institute of
Chemistry, Leiden University, Leiden, The Netherlands. 5Leiden Institute of
Chemistry, Gorlaeus Laboratory, room number 0.3.15, Einsteinweg 55, 2300
RA Leiden, The Netherlands.
Received: 24 November 2015 Accepted: 16 March 2016
References
1. Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides II.
Evidence of an enzymatic deficiency in Gaucher disease. Biochem Biophys
Res Commun. 1965;18:221–5.
2. Dekker N, Voorn-Brouwer T, Verhoek M, Wennekes T, Narayan RS, Speijer D,
et al. The cytosolic beta-glucosidase GBA3 does not influence type 1
Gaucher disease manifestation. Blood Cells Mol Dis. 2011;46(1):19–26.
3. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic
response to intravenous infusions of glucocerebrosidase in a patient with
Gaucher disease. Proc Natl Acad Sci U S A. 1990;87(5):1913–6.
4. Beutler E, Kay A, Saven A, Garver P, Thurston D, Dawson A, et al. Enzyme
replacement therapy for Gaucher disease. Blood. 1991;78(5):1183–9.
5. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee
MA, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy
of mannose-terminated glucocerebrosidase from natural and recombinant
sources. Ann Intern Med. 1995;122(1):33–9.
6. Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, et al.
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease:
results from a randomized, double-blind, multinational, phase 3 study. Am J
Hematol. 2013;88(3):166–71.
7. Zimran A, Altarescu G, Phillips M, Attias D, Jmoudiak M, Deeb M, et al. Phase I/II
and extension study of velaglucerase alfa replacement therapy in adults with
type 1 Gaucher disease: 48-month experience. Blood. 2010;115(23):4651–46.
8. Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Munoz ET,
et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase,
taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease.
Blood. 2011;118(22):5767–73.
9. van Dussen L, Biegstraaten M, Dijkgraaf M, Hollak C. Modelling Gaucher
disease progression: long-term enzyme replacement therapy reduces the
incidence of splenectomy and bone complications. Orphanet J Rare Dis.
2014;9(1):112.
10. Md F, van Noesel CJ, Aerts JM, Maas M, Poll RG, Hollak CE. Persistent bone
disease in adult type 1 Gaucher disease despite increasing doses of enzyme
replacement therapy. Haematologica. 2008;93(7):1119–20.
11. Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, et al.
Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease
displaying cellular and molecular dysregulation beyond the macrophage.
Proc Natl Acad Sci U S A. 2010;107(45):19473–8.
12. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al.
Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin
(OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355(9214):1481–5.
13. Cox TM, Amato D, Hollak CE, Luzy C, Silkey M, Giorgino R, et al. Evaluation
of miglustat as maintenance therapy after enzyme therapy in adults with
stable type 1 Gaucher disease: a prospective, open-label non-inferiority
study. Orphanet J Rare Dis. 2012;7:102.
Smid et al. Orphanet Journal of Rare Diseases  (2016) 11:28 Page 11 of 12
14. Brand M, Muller A, Alsop J, van Schaik IN, Bembi B, Hughes D. Results from
a 9-year Intensive Safety Surveillance Scheme (IS3) in miglustat (Zavesca(®))-
treated patients. Pharmacoepidemiol Drug Saf. 2015;24(3):329–33.
15. Schiffmann R, Fitzgibbon EJ, Harris C, DeVile C, Davies EH, Abel L, et al.
Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann
Neurol. 2008;64(5):514–22.
16. Cox-Brinkman J, van Breemen MJ, van Maldegem BT, Bour L, Donker WE,
Hollak CE, et al. Potential efficacy of enzyme replacement and substrate
reduction therapy in three siblings with Gaucher disease type III. J Inherit
Metab Dis. 2008;31(6):745–52.
17. McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, et al.
A specific and potent inhibitor of glucosylceramide synthase for substrate
inhibition therapy of Gaucher disease. Mol Genet Metab. 2007;91(3):259–67.
18. Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H,
et al. Improvement in hematological, visceral, and skeletal manifestations of
Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment:
2-year results of a phase 2 study. Blood. 2010;116(20):4095–8.
19. Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, Iastrebner M,
et al. A Phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate
reduction therapy for Gaucher disease type 1. Blood. 2010;116(6):893–9.
20. Smid BE, Hollak CE. A systematic review on effectiveness and safety of eliglustat
for type 1 Gaucher disease. Expert Opinionon Orphan Drugs. 2014;2(5):523–9.
21. Mistry PK, Lukina E, Ben TH, Amato D, Baris H, Dasouki M, et al. Effect of oral
eliglustat on splenomegaly in patients with gaucher disease type 1: The
engage randomized clinical trial. JAMA. 2015;313(7):695–706.
22. Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins A, et al.
Eliglustat compared with imiglucerase in patients with Gaucher’s disease
type 1 stabilised on enzyme replacement therapy: a phase 3, randomised,
open-label, non-inferiority trial. Lancet. 2015;385(9985):2355–62.
23. Boot RG, Verhoek M, de Fost M, Hollak CE, Maas M, Bleijlevens B, et al. Marked
elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate
marker for assessing therapeutic intervention. Blood. 2004;103(1):33–9.
24. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma
chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest.
1994;93(3):1288–92.
25. Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JM, et al.
Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher
disease. Blood Cells Mol Dis. 2005;35(2):259–67.
26. van Dussen L, Hendriks EJ, Groener JEM, Boot RG, Hollak CEM, Aerts JMFG.
Value of plasma chitotriosidase to assess non-neuronopathic Gaucher
disease severity and progression in the era of enzyme replacement therapy.
J Inherit Metab Dis. 2014;37(6):991–1001.
27. Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM,
et al. The human chitotriosidase gene: Nature of inherited enzyme
deficiency. J Biol Chem. 1998;273(40):25680–5.
28. Schoonhoven A, Rudensky B, Elstein D, Zimran A, Hollak CE, Groener JE,
et al. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin
Chim Acta. 2007;381(2):136–9.
29. Bussink AP, Verhoek M, Vreede J, Ghauharali-van der Vlugt K, Donker-
Koopman WE, et al. Common G102S polymorphism in chitotriosidase
differentially affects activity towards 4-methylumbelliferyl substrates. FEBS J.
2009;276(19):5678–88.
30. Aguilera B, Ghauharali-vanderVlugt K, Helmond MT, Out JM, Donker-
Koopman WE, Groener JE, et al. Transglycosidase activity of chitotriosidase:
improved enzymatic assay for the human macrophage chitinase. J Biol
Chem. 2003;278(42):40911–6.
31. Dekker N, van Dussen L, Hollak CE, Overkleeft H, Scheij S, Ghauharali K, et al.
Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype,
storage cell markers, and therapeutic response. Blood. 2011;118(16):e118–27.
32. Ferraz MJ, Kallemeijn WW, Mirzaian M, Herrera Moro D, Marques A, Wisse P,
et al. Gaucher disease and Fabry disease: new markers and insights in
pathophysiology for two distinct glycosphingolipidoses. Biochim Biophys
Acta. 2014;1841(5):811–25.
33. Yamaguchi Y, Sasagasako N, Goto I, Kobayashi T. The synthetic pathway for
glucosylsphingosine in cultured fibroblasts. J Biochem. 1994;116(3):704–10.
34. Pavlova EV, Archer J, Wang S, Dekker N, Aerts JM, Karlsson S, et al. Inhibition
of UDP-glucosylceramide synthase in mice prevents Gaucher disease-
associated B-cell malignancy. J Pathol. 2015;235(1):113–24.
35. Pavlova EV, Wang SZ, Archer J, Dekker N, Aerts JM, Karlsson S, et al.
B cell lymphoma and myeloma in murine Gaucher’s disease. J Pathol.
2013;231(1):88–97.
36. Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, den Heeten GJ.
Quantification of skeletal involvement in adults with type I Gaucher’s
disease: fat fraction measured by Dixon quantitative chemical shift imaging
as a valid parameter. Am J Roentgenol. 2002;179(4):961–5.
37. Mirzaian M, Wisse P, Ferraz MJ, Gold H, Donker-Koopman WE, Verhoek M, et
al. Mass spectrometric quantification of glucosylsphingosine in plasma and
urine of type 1 Gaucher patients using an isotope standard. Blood Cells Mol
Dis. 2015;54(4):307–14.
38. Groener JE, Poorthuis BJ, Kuiper S, Helmond MT, Hollak CE, Aerts JM. HPLC
for simultaneous quantification of total ceramide, glucosylceramide, and
ceramide trihexoside concentrations in plasma. Clin Chem. 2007;53(4):742–7.
39. Hollak CEM, Donker-Koopman W, Groener JA, Berge tIJM, Oers vMH, Aerts
JMFG. Progressive Gaucher disease due to neutralizing anti-imiglucerase
antibodies: successful treatment with Rituximab (anti-CD20) followed by
high dose imiglucerase. ESGLD conference, Bad Honnef. 2009.
40. Biegstraaten M, van Schaik IN, Aerts JM, Langeveld M, Mannens MM, Bour
LJ, et al. A monozygotic twin pair with highly discordant Gaucher
phenotypes. Blood Cells Mol Dis. 2011;46(1):39–41.
41. Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, et al. Sustained
therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT
918) in type I Gaucher disease. J Inherit Metab Dis. 2004;27(6):757–66.
42. Heitner R, Elstein D, Aerts J, Weely S, Zimran A. Low-dose N-
butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol
Dis. 2002;28(2):127–33.
43. Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, et al. Short-term
effect of miglustat in every day clinical use in treatment-naive or previously
treated patients with type 1 Gaucher’s disease. Haematologica.
2006;91(5):703–6.
44. Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, et al.
Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in
a multicenter retrospective cohort study. Blood Cells Mol Dis.
2013;51(2):116–24.
45. Giraldo P, Alfonso P, Atutxa K, Fernandez-Galan MA, Barez A, Franco R, et al.
Real-world clinical experience with long-term miglustat maintenance
therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica.
2009;94(12):1771–5.
46. Elstein D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Altarescu G, et al.
Oral maintenance clinical trial with miglustat for type I Gaucher disease:
switch from or combination with intravenous enzyme replacement. Blood.
2007;110(7):2296–301.
47. Orvisky E, Park JK, Lamarca ME, Ginns EI, Martin BM, Tayebi N, et al.
Glucosylsphingosine accumulation in tissues from patients with Gaucher
disease: correlation with phenotype and genotype. Mol Genet Metab.
2002;76(4):262–70.
48. Nilsson O, Svennerholm L. Accumulation of glucosylceramide and
glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile
and juvenile Gaucher disease. J Neurochem. 1982;39(3):709–18.
49. Schueler UH, Kolter T, Kaneski CR, Blusztajn JK, Herkenham M, Sandhoff K,
et al. Toxicity of glucosylsphingosine (glucopsychosine) to cultured
neuronal cells: a model system for assessing neuronal damage in Gaucher
disease type 2 and 3. Neurobiol Dis. 2003;14(3):595–601.
50. Arends M, van Dussen L, Biegstraaten M, Hollak CE. Malignancies and
monoclonal gammopathy in Gaucher disease; a systematic review of the
literature. Br J Haematol. 2013;161(6):832–42.
51. Langeveld M, Ghauharali KJ, Sauerwein HP, Ackermans MT, Groener JE,
Hollak CE, et al. Type I Gaucher disease, a glycosphingolipid storage
disorder, is associated with insulin resistance. J Clin Endocrinol Metab.
2008;93(3):845–51.
52. Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, et al.
Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM.
1996;89(9):691–4.
53. van Dussen L, Akkerman EM, Hollak CE, Nederveen AJ, Maas M. Evaluation
of an imaging biomarker, Dixon quantitative chemical shift imaging, in
Gaucher disease: lessons learned. J Inherit Metab Dis. 2014;37(6):1003–11.
Smid et al. Orphanet Journal of Rare Diseases  (2016) 11:28 Page 12 of 12
